Eight projects and eight cores are proposed forming a translational research program with the goal of advancing the treatment of chronic myelogenous leukemia. Projects 1-3 involve 1) clinical investigation of novel chemo- and biologic therapies, 2) allogeneic blood and marrow transplantation focusing on enhancement of graft-versus-leukemia and improving the therapeutic index of preparative regimen, and 3) Use of """"""""leukemic"""""""" dendritic cells to generate autologous anti-leukemic T-cells for adoptive immunotherapy. Projects 4 and 5 are designed to improve the safety and effectiveness of allogeneic transplants for CML. The allogeneic graft-versus-leukemia effect can independently produce prolonged remissions in CML patients,b ut its efficacy is limited by the development of graft-versus-host disease. Project 4 studies the induction of GVL using lymphocytes transduced with Herpes virus thymidine kinase which renders them sensitive to the antiviral drug ganciclovir; if GVHD occurs the effectors cells can be ablated by ganciclovir treatment. In a preclinical murine model, the hypothesis that this strategy can abrogate GVHD while retaining GVL will be tested and strategies for optimally employing TK transduced donor lymphocyte infusions will be developed. Project 5 focuses on development of less toxic preparative regimens to achieve engraftment of allogeneic stem cell grafts and strategies to induce GVL without GVHD in histoincompatible recipients. Projects 6 and 7 examine the function of the bcr-abl tyrosine kinase and molecular strategies to block its transforming effects. Project 8 examines abnormalities in DNA methylation which occur in the course of CML and their significance for therapeutic intervention. Core A is for administration. Core B provides biostatistical support for the program. Core C is for minimal disease detection using fluorescence in situ hybridization (C1) or quantitative polymerase chain reaction (C2). Core D is for cell culture assays, in vitro (D1) and in a NOD-SCID murine model (D2). Core E provides flow cytometry support and Core F is the sample collection, processing and distribution core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-11
Application #
6150090
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
1989-12-01
Project End
2003-05-31
Budget Start
2000-07-12
Budget End
2001-01-31
Support Year
11
Fiscal Year
2000
Total Cost
$1,903,897
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Schools of Medicine
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Gambacorti-Passerini, Carlo; Cortes, Jorge E; Lipton, Jeff H et al. (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298-1307
Boddu, Prajwal; Shah, Abdul Rashid; Borthakur, Gautam et al. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312-1322
Kornblau, Steven M; Ruvolo, Peter P; Wang, Rui-Yu et al. (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810-821
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Boddu, Prajwal; Benton, Christopher B; Wang, Wei et al. (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32:96-105
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W et al. (2018) Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237
Sasaki, Koji; Kantarjian, Hagop; O'Brien, Susan et al. (2018) Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124:1160-1168

Showing the most recent 10 out of 375 publications